“Currently, the only stem cell products, and a stem cell-based treatment routinely reviewed and approved by the U.S. Food and Drug Administration (FDA), are hematopoietic (or blood) stem cell transplantation.” (Harvard Stem Cell Institute)
There is currently a number of approaches addressing diseases of aging, ranging from small molecule pharmaceuticals and biologics to gene therapy and medical devices. Most of them are symptomatic, palliative, and marginally effective.
Stem cell treatment approach is believed to be one of the most promising for a long-term organ function improvement, but currently has its own drawbacks.
Universal Donor Stem Cells (allogeneic), the most common approach suggested to be used to rejuvenate an organ, often lead to rejection. It is also often not the stem cells themselves, but exosomes and apoptotic bodies that offer a potential short-term solution.
Current techniques of using a patient’s own adult stem cells (autologous), obtained when such need occurs, provide no tissue rejection, but they are mostly already quite old by then, limited in numbers, and, therefore, have inadequate effectiveness.
Immorta Bio unique method focuses on the development and use of Stem Cells that are young, received from somatic cells of the patient, and can be produced in unlimited quantities. These features are uniquely associated with
autologous pluripotent stem cells (APSC)
Stem Cell Revivify™: rejuvenation of a damaged organ to the healthy state
using Immorta Bio Innovative Solution
“Aging is a gradual and irreversible pathophysiological process. It presents with declines in tissue and cell functions, and significant increases in the risks of various aging-related diseases…” Nature, 16 December 2022
As we become older, a number of ailments accumulate, and it is inevitable that eventually, we will succumb to one or a combination of those. Our cells, organs, and the whole body are prone to crumbling with age. Diseases of aging are a manifestation of aging itself. When we treat diseases of aging, we are treating aging as a disease.
Our Mission is to develop efficient and practical technology platforms that can be used in treating Diseases of Aging and Treating Aging as Disease™. We leverage autologous pluripotent stem cells to derive unlimited young Personalized Progenitor Cells (PPC) as the core of Immorta Bio therapeutics pipeline.
Revolutionary iPSC technology was pioneered by Shinya Yamanaka, who showed that the introduction of specific genes, collectively known as Yamanaka factors, could convert somatic cells into pluripotent stem cells. Shinya Yamanaka was awarded the 2012 Nobel Prize "for the discovery that mature cells can be reprogrammed to become pluripotent
Human induced pluripotent stem cells (iPSCs) are derived from skin or blood cells reprogrammed back into an embryonic-like pluripotent state, enabling the development of an unlimited source for any type of human cells needed for therapeutic purposes.
Amenable Stem Cells (ASC) are blood-derived stem cells, providing the most efficient path for transforming them into Personalized Regenerative Cells (PRC). PRC are pluripotent, autologous stem cells that can be differentiated into multiple organ-specific tissues.
Immorta Bio's innovative approach calls for the efficient laboratory generation of naturally occurring cells, PPC, dedicated to repairing a damaged organ. Those cells are administered in quantities required to achieve organ rejuvenation, a state Immorta Bio calls Stem Cell Revivify™.
A multipotent pMSC, when induced into pluripotence, holds great promise to slow or reverse aging phenotypes. In 2020, Stanford University researchers concluded, after studying elderly mice, that old human cells, when subjected to the Yamanaka factors, might rejuvenate and become nearly indistinguishable from their younger counterparts.
.webp)
Immorta Bio embodies a team-centric ethos, comprising highly devoted and skilled individuals. Our collaborative teams operate synergistically within a dynamic, enjoyable, and creatively fulfilling environment. Upholding principles of high integrity, mutual respect, teamwork, open-mindedness, and scientific excellence, we prioritize recruiting, developing, and retaining individuals possessing the determination and expertise essential for success.
We provide compelling career opportunities for individuals passionate about life extension and dedicated to supporting advancements in the biotechnology field.
Thank you for being part of the END OF AGING
